CCHT(SZ:000661)2026-02-27 03:10Summary of Longcheng Gaoxin (000661.SZ) Conference Call Company Overview - Company: Longcheng Gaoxin (000661.SZ) - Industry: Pediatric Rare Diseases Core Insights - The market perception of Longcheng Gaoxin remains limited to "growth hormone dependency," overlooking the company's significant investments in the pediatric rare disease sector [1] - GenSci141 ointment, the world's first First-in-class topical medication for pathological micropenis in children, has recently received clinical approval, marking a step closer to commercialization [1] Market Potential and Product Insights - GenSci141 is expected to replicate the commercial success of growth hormones due to its four core elements: "global innovation, rare disease necessity, pediatric channel reuse, and high pricing power" [2] - Estimated total market potential for GenSci141 in China is projected to reach 30-40 billion CNY, with potential doubling to 60-80 billion CNY if successfully launched overseas, which could offset performance pressures from growth hormone procurement [2] Market Space Re-evaluation 1. Target Population and Penetration Rate: - The incidence rate for pathological micropenis is 0.03%, ensuring medical seriousness and payment rigidity [3] - Current stock of male children aged 3-12 in China is approximately 36,000, with an annual addition of about 2,100 new cases [3] - Expected penetration rate of 30% by the fifth year post-launch, supported by GenSci's strong pediatric physician education system [3] 2. Pricing and Revenue Projections: - High pricing power due to the unique nature of the product with no direct competitors; estimated annual treatment cost is 45,000 CNY [3] - Steady-state revenue is projected to be between 486 million CNY (neutral) and 792 million CNY (optimistic) five years post-launch [3] - Total lifecycle value in China is estimated at approximately 3.42 billion CNY [3] 3. Performance Elasticity and Channel Reuse: - The expected steady-state revenue of 486 million CNY would account for about 6.5% of current revenue for Jinsai Pharmaceutical, marking it as the most certain incremental growth after growth hormones [4] - The product will fully utilize existing pediatric channels, ensuring high commercialization efficiency without significant additional sales costs [4] Company Fundamentals - The company has moved past its transformation pains, with positive signals accumulating: 1. Management changes with the return of key technical figure Jin Lei as Group General Manager, shifting strategic focus towards innovative drugs [5] 2. Increased R&D expenditure, reaching 1.733 billion CNY in the first three quarters of 2025, supporting a robust innovation pipeline [5] 3. Significant pipeline progress with the oral small molecule growth hormone secretagogue (GS3-007a) for idiopathic short stature (ISS) also receiving clinical acceptance [6] Profit Forecast and Valuation - Profit forecasts indicate net profits of 2.119 billion CNY, 2.296 billion CNY, and 2.517 billion CNY for 2025-2027 [7] - Current stock price corresponds to a PE ratio of less than 20 for 2026, at historical valuation lows; potential for significant valuation recovery as the value of innovative pipelines is recognized [7] - Target price estimated at over 144.48 CNY based on a 28x PE ratio for 2025 [7] Risk Factors 1. Clinical and approval risks for GenSci141, with uncertainties surrounding Phase III trials and market approval [8] 2. Limitations on expanding indications could restrict market potential if future off-label uses are strictly regulated [8] 3. Ongoing procurement pressures on the core growth hormone business and potential competition from similar mechanism drugs could alter the competitive landscape [8] Conclusion Longcheng Gaoxin is at a critical juncture with its "old business bottoming out and new business breakthroughs." The GenSci141 ointment, with its unique global innovation and pediatric necessity, is poised to be a key driver for the company to navigate through cycles [9][10]